NASDAQ:ARCT Arcturus Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.28 +2.12 (+13.12%) (As of 07/5/2022 02:22 PM ET) Add Compare Share Today's Range$15.55▼$18.5150-Day Range$12.26▼$22.5952-Week Range$11.70▼$65.00Volume25,162 shsAverage Volume811,596 shsMarket Capitalization$482.96 millionP/E RatioN/ADividend YieldN/APrice Target$39.75 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arcturus Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside117.1% Upside$39.75 Price TargetShort InterestBearish14.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($6.66) to $2.00 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.59 out of 5 starsMedical Sector712th out of 1,428 stocksPharmaceutical Preparations Industry351st out of 680 stocks 3.0 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 3 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $39.75, Arcturus Therapeutics has a forecasted upside of 117.1% from its current price of $18.31.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.86% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Arcturus Therapeutics has recently increased by 1.20%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 1.6 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arcturus Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.10% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($6.66) to $2.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Arcturus Therapeutics (NASDAQ:ARCT) StockArcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.Read More ARCT Stock News HeadlinesJuly 3, 2022 | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $33.14 Average PT from AnalystsJune 22, 2022 | seekingalpha.comArcturus gains on reports to draw takeover interest, blog report claimsJune 10, 2022 | finance.yahoo.comArcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their strong 147% return over the last three yearsJune 1, 2022 | businessinsider.comEmployees at top biotech companies can get paid up to $1.6 million. Here's where workers made the most in 2021.May 12, 2022 | nasdaq.comBuying Power of Ethereum vs. Arcturus Therapeutics at New 52-Week HighMay 11, 2022 | finance.yahoo.comNeed To Know: The Consensus Just Cut Its Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Estimates For 2022May 10, 2022 | seekingalpha.comArcturus Therapeutics Holdings Inc. (ARCT) CEO Joseph Payne on Q1 2022 Results - Earnings Call TranscriptMay 9, 2022 | investing.comArcturus Therapeutics Tops Q1 EPS by 338cMay 6, 2022 | seekingalpha.comArcturus Therapeutics Q1 2022 Earnings PreviewMay 5, 2022 | finance.yahoo.comArcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster TrialMay 5, 2022 | finance.yahoo.comArcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster TrialMay 5, 2022 | finance.yahoo.comCORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster TrialMay 4, 2022 | finance.yahoo.comVaccine Makers Slump as Moderna, Pfizer Leave Full-Year Guidance IntactMay 2, 2022 | washingtonpost.comBetter Vaccines Are in Sight — for the Next PandemicMay 1, 2022 | finance.yahoo.comWhen Will Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Breakeven?April 27, 2022 | finance.yahoo.comArcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022April 25, 2022 | msn.comExplained: How self-replicating mRNA Covid-19 vaccines work, and what trial results showApril 25, 2022 | seekingalpha.comArcturus: Biotech With Great Potential In Covid-19 Vaccine SpaceApril 21, 2022 | seekingalpha.comHot Stocks: AAL, WSO, STLD climb on earnings news; ARCT drops after downgradeApril 21, 2022 | seekingalpha.comArcturus cut to Neutral at Citi on COVID vaccine ARCT-154 'too risky' path aheadApril 20, 2022 | finance.yahoo.comArcturus' COVID-19 Vaccine Candidate Meets Primary Goal In Vietnam StudyApril 20, 2022 | marketwatch.comArcturus Therapeutics Trial for Covid-19 Vaccine Candidate Meets Primary EndpointApril 20, 2022 | seekingalpha.comArcturus falls even as Piper Sandler backs COVID-19 vaccine dataApril 20, 2022 | marketwatch.comArcturus Therapeutics Shares Drop 20% After Data for Covid-19 Vaccine CandidateMarch 31, 2022 | americanbankingnews.comArcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at StockNews.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees177Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today7/05/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$39.75 High Stock Price Forecast$105.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+117.5%Consensus RatingHold Rating Score (0-4)2 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($7.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-203,700,000.00 Net Margins-1,282.62% Pretax MarginN/A Return on Equity-64.94% Return on Assets-44.23% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$12.40 million Price / Sales38.95 Cash FlowN/A Price / Cash FlowN/A Book Value$16.19 per share Price / Book1.13Miscellaneous Outstanding Shares26,420,000Free Float23,196,000Market Cap$482.96 million OptionableOptionable Beta2.79 Arcturus Therapeutics Frequently Asked Questions Should I buy or sell Arcturus Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares. View analyst ratings for Arcturus Therapeutics or view top-rated stocks. What is Arcturus Therapeutics' stock price forecast for 2022? 7 equities research analysts have issued 12 month price targets for Arcturus Therapeutics' stock. Their ARCT stock forecasts range from $8.00 to $105.00. On average, they anticipate Arcturus Therapeutics' share price to reach $39.75 in the next twelve months. This suggests a possible upside of 119.4% from the stock's current price. View analysts' price targets for Arcturus Therapeutics or view top-rated stocks among Wall Street analysts. How has Arcturus Therapeutics' stock performed in 2022? Arcturus Therapeutics' stock was trading at $37.01 on January 1st, 2022. Since then, ARCT stock has decreased by 51.0% and is now trading at $18.12. View the best growth stocks for 2022 here. When is Arcturus Therapeutics' next earnings date? Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Arcturus Therapeutics. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) issued its earnings results on Monday, May, 9th. The biotechnology company reported ($1.94) EPS for the quarter, missing the consensus estimate of ($1.29) by $0.65. The biotechnology company had revenue of $5.24 million for the quarter, compared to the consensus estimate of $3.26 million. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 64.94% and a negative net margin of 1,282.62%. During the same period last year, the company posted ($2.15) EPS. View Arcturus Therapeutics' earnings history. Who are Arcturus Therapeutics' key executives? Arcturus Therapeutics' management team includes the following people: Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 50, Pay $960k)Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 43, Pay $750k)Mr. Andrew H. Sassine MBA, CFO & Director (Age 58, Pay $750k)Mr. Lance Kurata, Chief Legal OfficerDr. Steven George Hughes M.B.A., M.D., Strategic Clinical Advisor & Member of Scientific Advisory Board (Age 54, Pay $644k)Mr. Keith C. Kummerfeld CPA, VP of Fin. & Corp. ControllerDr. Dushyant B. Varshney Ph.D., Exec. VP & Chief Technology OfficerMr. Deepankar Roy, Sr. Director of Investor RelationsMr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance ManagementDr. Kelly A. Lindert M.D., Chief Devel. Officer of Vaccines What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees. Who are some of Arcturus Therapeutics' key competitors? Some companies that are related to Arcturus Therapeutics include Ironwood Pharmaceuticals (IRWD), ChemoCentryx (CCXI), OPKO Health (OPK), Xencor (XNCR), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX), Amphastar Pharmaceuticals (AMPH), Emergent BioSolutions (EBS), Xenon Pharmaceuticals (XENE), Cryoport (CYRX), Ligand Pharmaceuticals (LGND), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Axsome Therapeutics (AXSM) and BridgeBio Pharma (BBIO). View all of ARCT's competitors. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY). What is Arcturus Therapeutics' stock symbol? Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT." How do I buy shares of Arcturus Therapeutics? Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcturus Therapeutics' stock price today? One share of ARCT stock can currently be purchased for approximately $18.12. How much money does Arcturus Therapeutics make? Arcturus Therapeutics (NASDAQ:ARCT) has a market capitalization of $478.73 million and generates $12.40 million in revenue each year. The biotechnology company earns $-203,700,000.00 in net income (profit) each year or ($7.53) on an earnings per share basis. How many employees does Arcturus Therapeutics have? Arcturus Therapeutics employs 177 workers across the globe. How can I contact Arcturus Therapeutics? Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for Arcturus Therapeutics is www.arcturusrx.com. The biotechnology company can be reached via phone at (858) 900-2660 or via email at ir@arcturusrx.com. This page (NASDAQ:ARCT) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
